Description

(R)-2-((6-(3-((3-(2-cyanobenzyl)-1-Methyl-2,6-dioxo-1,2,3,6-tetrahydropyriMidin-4-yl)aMino)piperidin-1-yl)-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)Methyl)benzonitrile is a high-purity, chiral small molecule building block of significant interest in advanced pharmaceutical research and development. Its complex heterocyclic structure, featuring multiple uracil-like moieties, makes it a critical intermediate for synthesizing novel therapeutic agents. This compound is primarily sought after by pharmaceutical R&D organizations and contract research and manufacturing services (CRAMS) focused on oncology, virology, and other targeted disease areas.

Application

• Pharmaceutical Intermediate: Serves as a key chiral scaffold in the synthesis of novel drug candidates, particularly protease inhibitors and targeted protein degraders (PROTACs).
• Medicinal Chemistry Research: Used in structure-activity relationship (SAR) studies and lead optimization programs due to its complex, multi-functional architecture.
• Biochemical Tool Compound: Acts as a reference standard or a selective ligand in enzymatic assays and target validation studies.
• Preclinical Development: Employed in the production of batches for pharmacokinetic, pharmacodynamic, and toxicology studies.
• Academic Research: Utilized in universities and research institutes for exploring new synthetic methodologies and biological pathways.

Basic Information

Product Name	(R)-2-((6-(3-((3-(2-cyanobenzyl)-1-Methyl-2,6-dioxo-1,2,3,6-tetrahydropyriMidin-4-yl)aMino)piperidin-1-yl)-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)Methyl)benzonitrile
CAS No.	1268836-55-0
Molecular Formula	C31H30N8O4
Molecular Weight	578.63 g/mol
Synonyms	(R)-enantiomer of BMS-986195; (R)-BMS-986195; (R)-2-((6-(3-((3-(2-Cyanobenzyl)-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)amino)piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; UNII-9Q7VU4B9R8; BMS 986195 (R-enantiomer); 9Q7VU4B9R8; (R)-BMS986195
EINECS	Contact for details

Quality Control

Every batch of this advanced pharmaceutical intermediate is produced under strict quality management systems. We provide comprehensive analytical data to support your regulatory filings, including HPLC purity, chiral purity (enantiomeric excess), and identity confirmation via spectroscopic methods. A detailed Certificate of Analysis (COA) is supplied with each shipment, documenting compliance with your specified requirements. Our quality protocols are designed to meet the standards expected in GMP-like environments for non-clinical and early-phase clinical material.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) or as specified on the label or COA. The compound is moisture-sensitive; keep the container in a dry environment. For long-term storage, consider storing under an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Chiral Purity (Chiral HPLC)	≥ 99.0% ee
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.